Trials / Conditions / Eosinophilic Asthma

Eosinophilic Asthma

28 registered clinical trials studyying Eosinophilic Asthma — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma NCT07323654	Kymera Therapeutics, Inc.	Phase 2
Not Yet Recruiting	A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophil NCT07250594	Advagene Biopharma Co. Ltd.	Phase 2
Enrolling By Invitation	Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in NCT07343661	Azienda Ospedaliero Universitaria di Cagliari	Phase 4
Not Yet Recruiting	Eosinophil Subpopulations in Eosinophilic-associated Diseases NCT06911775	University of Florence	—
Recruiting	Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in NCT06750289	AstraZeneca	Phase 3
Terminated	Phase III Long-Term Extension Study With Dexpramipexole NCT06388889	Areteia Therapeutics	Phase 3
Completed	AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma NCT05985694	Advagene Biopharma Co. Ltd.	Phase 1 / Phase 2
Terminated	A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHA NCT05813288	Areteia Therapeutics	Phase 3
Terminated	A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. NCT05763121	Areteia Therapeutics	Phase 3
Active Not Recruiting	A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma NCT05748600	Areteia Therapeutics	Phase 3
Unknown	Effect of Mepolizumab on Severe Eosinophilic Asthma NCT04641741	Hospital Clinico Universitario de Santiago	—
Completed	Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma NCT05002621	Mayo Clinic	—
Completed	XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma NCT04674137	Chemlmmune Therapeutics LLC	Phase 2
Completed	Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma NCT04671446	Queen Mary University of London	—
Unknown	Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma NCT05398133	Medical University of Warsaw	—
Unknown	Eosinophils Endotypes in Chronic Airway Inflammatory Diseases NCT04187976	University Hospital, Lille	—
Recruiting	Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying a NCT04538937	Medical University Innsbruck	—
Unknown	A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazi NCT04228588	University of Sao Paulo General Hospital	Phase 4
Completed	Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma NCT04046939	Knopp Biosciences	Phase 2
Unknown	Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab". NCT04585997	University of Newcastle, Australia	Phase 4
Completed	Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma NCT03563521	TC Erciyes University	—
Completed	Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophili NCT03469934	AnaptysBio, Inc.	Phase 2
Completed	Intense Airway Eosinophilia in Asthma NCT03696914	Laval University	—
Completed	Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma NCT01508936	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 3
Terminated	Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatmen NCT01290887	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 3
Completed	A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exac NCT01287039	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 3
Completed	A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma NCT01285323	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 3
Completed	A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 NCT01270464	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 3